Third-party tested
Discreet shipping
Catalog/Semaglutide
Semaglutide
#1001
Lyophilized Peptide

Semaglutide

10mg

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes and subsequently approved for chronic weight management. It is a 31-amino acid peptide analog of human GLP-1(7-37) with a C-18 fatty diacid chain attached via a linker to Lys26, conferring high albumin binding affinity and resistance to DPP-4 degradation. This structural modification extends its pharmacokinetic half-life to approximately 7 days, enabling once-weekly administration in clinical settings.

Pricing

Single (10mg)$100.00
10 vials
Save 50%
$500.00

Quantity

1
= $100.00
Buy now

Mechanism of Action

Semaglutide activates the GLP-1 receptor, a class B G-protein coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, and the central nervous system. Receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and modulates hypothalamic appetite circuits to reduce food intake. In research models, semaglutide has demonstrated effects on hepatic lipid metabolism, cardiovascular inflammation markers, and neuroinflammatory pathways.

Properties

Molecular Formula

C₁₈₇H₂₉₁N₄₅O₅₉

Molecular Weight

4113.58 Da

Sequence

His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 diacid-γGlu-OEG-OEG)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

Half-Life

~7 days (albumin-bound)

Storage

Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.

Research Applications

1Metabolic syndrome and insulin resistance modeling
2Appetite regulation and energy homeostasis studies
3Cardiovascular risk biomarker research (MACE outcomes)
4Hepatic steatosis and NASH investigation
5Neurodegenerative disease models (Alzheimer's, Parkinson's)

References & Citations

(4)
1

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Wilding JPH, Batterham RL, Calanna S, et al.

N Engl J Med (2021)PMID: 33567185 DOI
2

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)

Marso SP, Bain SC, Consoli A, et al.

N Engl J Med (2016)PMID: 27633186 DOI
3

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Newsome PN, Buchholtz K, Cusi K, et al.

N Engl J Med (2021)PMID: 33185364 DOI
4

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)

Kaplan A, Bhatt DL, et al.

N Engl J Med (2023)PMID: 37952131 DOI

Research Use Only

This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.